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Experimental Endourology
Ureteral Access Sheath Influence on the Ureteral Wall
Evaluated by Cyclooxygenase-2 and Tumor Necrosis
Factor-a in a Porcine Model
Søren Kissow Lildal, MD,1,2 Rikke Nørregaard, PhD,3 Kim Hovgaard Andreassen, MD,1,2
Frederikke Eichner Christiansen, MD,1,2 Helene Jung, MD, PhD,1,2
Malene Roland Pedersen,2,4 and Palle Jo¨rn Sloth Osther, MD, PhD1,2
Abstract
Objective: To examine the effect of ureteral access sheath (UAS) on the expression of the pro-inflammatory
mediators cyclooxygenase-2 (COX-2) and tumor necrosis factor-a (TNF-a) in the ureteral wall.
Material and Methods: In 22 pigs an UAS was inserted and removed after 2 minutes on one side and 2 hours
on the contralateral side. Postoperatively ureters were excised in vivo, and tissue samples from the distal
(2 minutes/2 hours) and proximal ureter (2 minutes/2 hours) were snap-frozen before quantitative polymerase
chain reaction analysis of COX-2 and TNF-a. Five unmanipulated ureteral units from other pigs served as the
control group.
Results: Compared to controls COX-2 mRNA was significantly upregulated in all UAS treated ureteral groups.
Similarly, TNF-a mRNA was upregulated in all groups except the 2-minute proximal ureteral group. Both
COX-2 and TNF-a expression were significantly higher in the distal than in the proximal ureter in the UAS
treated ureters. After UAS insertion for 2 minutes, expression levels in the distal ureter were increased 6.5- and
8-fold for COX-2 and TNF-a, respectively; and after 2 hours of UAS placement COX-2 and TNF-a mRNA
expression levels were increased 9- and 9.5-fold, respectively.
Conclusion: The pro-inflammatory mediators COX-2 and TNF-a were significantly upregulated in the ureteral
wall by the influence of UAS. These findings may have implications for postoperative pain, drainage, and
complications.
Keywords: ureter, ureteral access sheath, cyclooxygenase-2, tumor necrosis factor-a, ureteroscopy, complications
Introduction
Using ureteral access sheath (UAS) in retrogradeintrarenal surgery (RIRS) has several advantages, such
as reducing intrarenal pressure and easing multiple
reentries.1–4 A downside of UAS usage is the risk of harming
the ureteral wall, when inserting an instrument of larger di-
ameter than the scope itself.3,5 Furthermore, by keeping the
UAS in situ during the operation, ischemic and inflammatory
changes may be induced, potentially leading to temporary or
chronic changes in the function of the ureter.6,7 Such changes
may not be recognized during the endoscopic procedure, but
may be involved in the pathogenesis of postoperative pain,
drainage problems, and complications.6
Pro-inflammatory mediators cyclooxygenase-2 (COX-2)
and tumor necrosis factor-a (TNF-a) are increased in the ur-
eteral wall by the influence of UAS.8–12 Elevated COX-2 ex-
pression is known to occur in urothelial cells during urinary
tract obstruction, which increases COX-2-dependent prosta-
noid synthesis.9 Inhibition of cyclooxygenase (COX) activity
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with nonsteroidal anti-inflammatory drugs (NSAIDs) has
proven to reduce pain in patients with ureteral colic or ob-
struction13 and intrarenal pressure and ureteral contractility
in animal and in vitro experiments.9,14 TNF-a is a well-
known pro-inflammatory and cytotoxic cytokine that can in-
duce apoptosis in many different cells in the organism and in
the urinary system it is involved in pathologic renal conditions
such as ischemia–reperfusion injury and obstructive uropathy,
being synthesized in renal tubular epithelial cells and infiltrat-
ing macrophages.15,16 Based on these findings we hypothe-
sized that ureteral wall distention due to UAS placement may
lead to upregulation of COX-2 and TNF-a, which subse-
quently could play an important role in postoperative symp-
toms and ureteral malfunction after UAS usage. We tested this
hypothesis in a porcine model.
Materials and Methods
Experimental animals and surgical procedure
Before the study, a pilot study was performed, in which the
most appropriate UAS size was selected. The ureter size of
the type of pigs evaluated in the present study was found to be
slightly larger than human ureters. The clinical feeling of
placing a 13/15F UAS in the pigs was equivalent to placing
12/14F UASs in human ureters, and therefore, this UAS size
was chosen for the experiment.
The animal protocols were approved by The National
Animal Experiments Inspectorate (Copenhagen, Denmark).
Studies were performed on 27 anesthetized female pigs (in-
cluding five controls) weighing 55 kg (Pa˚skehøjga˚rd, Ølsted,
Denmark). The pigs were fed a standard diet during breeding.
Before the study they had access to water, but were fasting
12 hours before anesthesia.
After premedication with azaperone (4mg/kg) and mid-
azolam (4mg/kg), anesthesia was induced by propofol (4–
20mg/kg) and maintained with sevoflurane (1.2 MAC) and
fentanil (0.03mg/kg/hours). The pigs were orotracheally in-
tubated and mechanically ventilated (GE Healthcare S5
Avance). Hydration was maintained by administration of
saline (9 g/L sodium chloride; 10mL/kg/hours) at a temper-
ature of 37C through an ear vein.
A cystoscope was inserted through the urethra into the
bladder. A ureteral catheter (Selectip; Bard Medical, Cov-
ington, GA) was placed in the distal part of the ureter, and
a retrograde pyelography was performed to visualize the anat-
omy of the upper urinary tract. A guidewire (Sensor; Boston
Scientific, Marlborough, MA) was placed through the ureteral
catheter to the renal pelvis, and the cystoscope was removed.
Over the guidewire a hydrophilic UAS (NavigatorUreteral
Access Sheath; Boston Scientific) 13/15F was inserted on one
side and removed after 2 minutes. The insertion procedure was
repeated on the contralateral side, where the UAS was left in
position for 2 hours before extraction. UAS placement was
controlled by fluoroscopy, ensuring that all UASs reached the
proximal part of the ureter. UAS insertion was performed by
two experienced endourologists (K.H.A., P.J.S.O.). During in-
sertion of the UASs no excessive resistance was encountered. A
safety wire was not placed outside the sheath. Although this is
often clinical practice, this was avoided to secure uniform
treatment of all ureters and to rule out the possibility that the
safety wire would cause local damage leading to inflammation
in the analyzed tissue.
Through a midline abdominal incision both ureters were
exposed and carefully excised in vivo between the ureter-
opelvic junction and the ureterovesical junction. One centi-
meter of ureteral tissue was collected from the distal and
proximal ureter, respectively. This specimen was prepared
further below/above the resection line, in order not to examine
tissue close to the surgical trauma and to ensure examining
tissue affected by the UAS. The surrounding fat and serosa
weremeticulously removedwithinminutes before thematerial
was snap-frozen in liquid nitrogen and stored at -80C.
Finally, the pigs were euthanized under anesthesia with
20mL of pentobarbital, 200mg/mL.
Quantitative polymerase chain reaction
Total RNA was isolated using TRIzol Reagent (Life
Technologies, Thermo Fisher Scientific, Cambridge, MA)
according to manufacturer’s instructions. RNA was quanti-
tated by spectrophotometry and stored at -80C. cDNA was
synthesized from 0.5 lg RNA with the AffinityScript QPCR
cDNA Synthesis Kit (Life Technologies, Thermo Fisher
Scientific). For quantitative polymerase chain reaction (q-PCR),
100 ng cDNA served as a template for PCR amplification
using Brilliant SYBR Green QPCR Master Mix according to
the manufacturer’s instruction (Life Technologies). mRNA
levels were validated by an Aria Mx3000P q-PCR System
(Agilent Technologies, Santa Clara, CA) with b-actin as a
control gene. A standard curve was constructed by plotting
threshold cycle (Ct values) against serial dilutions of cDNA.
The following primer sequences were used: COX-2: sense
5¢-CAA AAC CGT ATT GCT GCT GA-3¢ and antisense 5¢-
CAA AAC CGT ATT GCT GCT GA-3¢; TNF-a: sense
5¢-GGC TGC CTT GGT TCA GAT GT-3¢ and antisense 5¢-
CAG GTG GGA GCA ACC TAC AGT T-3¢; and b-actin:
sense 5¢-CAT CAC CAT TGG CAA TGA GCG-3¢ and an-
tisense 5¢-CTA GAA GCA TTT GCG GTG GAC-3¢. Sam-
ples were amplified in duplicate in 96-well plates, and PCR
was performed for 40 cycles consisting of denaturation for 30
seconds at 95C followed by annealing and polymerization at
60C for 1 minute. Emitted fluorescence was detected during
the annealing/extension step in each cycle.
Statistics
COX-2 and TNF-a mRNA results from the samples were
normalized for b-actin. Values are presented as group mean–
SEM and 95% confidence intervals. Statistical comparisons
between experimental groups were made by a standard two-
sample t-test following log transformation of data for normal-
ity. p< 0.05 was considered significant.
Results
Bilateral proximal and distal ureteral tissue samples were
collected from all 22 pigs treated with UAS, resulting in 22
distal and proximal 2-minute samples and 22 distal and
proximal 2-hour samples. Five age- and weight-matched pigs
served as controls.
During q-PCR analysis, two of the short-term UAS treat-
ment specimens were excluded from the study because of an
error in sampling and isolation of RNA.
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COX-2 expression in the ureteral wall was increased
in response to the use of UAS
COX-2 mRNA expression from control ureters yielded
low levels, and there was no difference between the distal and
the proximal ureter ( p = 0.79) (Table 1; Figs. 1 and 2).
In the 2-hour UAS treatment group COX-2 mRNA ex-
pressionwasmarkedly increased in both the distal ( p< 0.0001)
and proximal ureter ( p< 0.05), compared to controls (Fig. 2).
Expression was raised 9-fold in the distal ureter and 4.5-fold in
the proximal ureter (Fig. 1). In addition, expression was more
than doubled in the distal compared to the proximal ureter
( p< 0.001), (Figs. 1 and 2). After only 2 minutes followed by a
period of 2 hours of rest and reperfusion, expression was in-
creased 6.5-fold distally ( p< 0.0001) and 3-fold proximally
( p < 0.01), compared to controls (Figs. 1 and 2). In the 2-
minute group the expression was also significantly more el-
evated ( p < 0.05) in the distal compared to the proximal
ureter (Figs. 1 and 2).
TNF-a expression in the ureteral wall was increased
in response to the use of UAS
TNF-amRNAexpression in controls was low, and there was
no difference between distal and proximal ureter (p= 0.28)
(Table 2; Figs. 3 and 4). In the treatment groups, we found
highly elevated levels of expression in the ureteral wall
(Table 2; Figs. 3 and 4). Following 2-hour UAS placement,
TNF-a was increased 9.5-fold in the distal ureter ( p<0.001)
and 2-fold proximally (p<0.05), compared to controls (Figs. 3
and 4). Similar to COX-2 expression, short-term treatment also
resulted in marked and significant increase of TNF-a expression
level in the distal ureter compared to controls ( p<0.001) (Figs. 3
and 4). The expression levels were not significantly increased in
the proximal ureter. Both 2 hours and 2 minutes of UAS
placement resulted in higher TNF-a levels in distal compared to
proximal ureteral samples (Figs. 3 and 4). No significant dif-
ferences were found between the 2-hour and 2-minute group.
Table 1. Ureteral Cyclooxygenase-2 mRNA
Expression (Arbitrary Units) in Controls
and Ureteral Access Sheath Treated Animals
COX-2
Control
prox
Control
dist
2
minutes
prox
2
minutes
dist
2
hours
prox
2
hours
dist
N 5 5 20 22 22 22
Mean 0.11 0.13 0.35a 0.83a,b 0.48a 1.17a,b
SD 0.05 0.07 0.29 0.57 0.49 1.10
SEM 0.02 0.03 0.09 0.18 0.11 0.25
Number of animals, Mean value, SD, and SEM for each study
group divided into subgroups of distal and proximal ureteral samples.
ap < 0.05 (0.05–0.0001) compared with controls.
bp < 0.05 (0.05–0.0001) distal part of the ureter compared with the
proximal part within each group.
COX-2 = cyclooxygenase-2.
FIG. 1. Ureteral expression of COX-2 mRNA (arbitrary
units). The depicted values are calculated group means ac-
cording to Table 1. *p < 0.05 (0.05–0.0001) compared with
controls. $p < 0.05 (0.05–0.0001) distal part of the ureter
compared with the proximal part within each group. Short
term = 2 minutes. COX-2 = cyclooxygenase-2.
FIG. 2. Log-transformed values of the measured COX-2
mRNA expression normalized for b-actin (95% CI).
*p< 0.05 (0.05–0.0001) compared with controls. $p < 0.05
(0.05–0.0001) distal part of the ureter compared with the
proximal part within each group. Short term= 2 minutes. CI=
confidence interval.
Table 2. Ureteral Tumor Necrosis Factor-a mRNA
Expression (Arbitrary Units) in Controls
and Ureteral Access Sheath Treated Animals
TNF-a
Control
prox
Control
dist
2
minutes
prox
2
minutes
dist
2
hours
prox
2
hours
dist
N 5 5 20 22 22 22
Mean 0.35 0.25 0.67 2.02a,b 0.72a 2.48a,b
SD 0.16 0.12 0.52 2.60 0.50 4.00
SEM 0.07 0.05 0.16 0.82 0.11 0.89
Number of animals, Mean value, SD, and SEM for each study
group divided into subgroups of distal and proximal ureteral
samples.
ap < 0.05 (0.05–0.001) compared with controls.
bp < 0.05 (0.05–0.005) distal part of the ureter compared with the
proximal part within each group.
TNF-a= tumor necrosis factor-a.
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Discussion
This porcine model intended to simulate the conditions
that exist during RIRS in humans using an average size UAS
and keeping this in situ in the ureter for 2 hours, which is
approximately the maximum duration of this type of operation.
Thereby,we aimed to create a plausible worst-case scenario for
ureteral wall ischemia and stretch.
It is obvious that forced manipulation of a UAS in a
narrow ureter may result in ureteral damage with subse-
quent risk of stricture development. In 359 patients, who
underwent RIRS for kidney stones with usage of 12/14F
UAS, ureteral wall lesions could be endoscopically visu-
alized in 46.5%, 13.4% representing high-grade, beyond the
mucosa, injuries.5 Even if ureteral lesions cannot be en-
doscopically visualized, UAS placement may cause reac-
tions in the urothelium and smooth muscle layers, as
reflected by postoperative pain and need for postoperative
drainage (Double-J stenting). The present data suggest that
pro-inflammatory mediators may be involved in such UAS
related morbidity.
Only a few studies have been performed to assess the risk
of UAS induced damage to the ureter, and most of the work
addressed visible ureteral lesions rather than ischemic and
inflammatory reactions.5,7,17 It has been shown that increased
wall tension in both acute and chronically obstructed ureters
in rabbits resulted in a significant decrease in smooth muscle
blood perfusion evaluated by laser Doppler measurements.18
Another animal study on swine showed that placing a 12/14F
UAS or larger for 70 minutes resulted in an initial decrease of
intraoperative ureteral wall blood flow to below 50% of
baseline. The ureters were excised and histologic exami-
nation found nuclear changes, inflammation, and ureteral-
wall thickening with collagen deposition,7 confirming our
findings that significant changes occur following ureteral
distention.
COX-2 and TNF-a in the ureter
It is known that obstruction leading to distention and
stretch of the ureter causes severe pain and altered con-
tractility.19–22 Prostanoids have been found to play a role in
the stimulation of these reactions.23–25 The prostanoids are
synthesized by conversion of arachidonic acid, and this
reaction is catalyzed by COX as the rate-limiting enzyme.9
COX-2 is relatively unexpressed under normal conditions
in most cells, whereas elevated levels are found during
inflammation.26 Elevated COX-2 expression is known to
occur in urothelial cells during urinary tract obstruction,
which increases COX-2-dependent prostanoid synthesis.9
Inhibition of COX activity leads to reduction of prostanoid
synthesis and correspondingly, NSAIDs may be used to
reduce pain and contractility in patients with ureteral colic
or obstruction.13,27,28
Previous studies have shown that both COX-2 mRNA and
protein levels are upregulated in chronically obstructed
human ureters,8 and immunohistochemical analysis has de-
tected COX-2 in both smooth muscle and urothelium.9 In a
human study, chronically obstructed ureters were found to
express four times more COX-2 mRNA than unobstructed
controls. The same study showed a four-fold induction in
COX-2 expression after 6 hours of acute ureteral ob-
struction in swine ureters harvested ex vivo.11 In a similar
study using mice subjected to unilateral ureteral obstruc-
tion, COX-2 levels in whole ureteral tissue extracts were
increased nine-fold after 6 hours compared to unobstructed
controls.10
A study in rats subjected to 24 hours of ureteral obstruction
showed an 18-fold increase in COX-2 mRNA in the proximal
obstructed part, compared to the distal unobstructed part.
Upon treatment with a selective COX-2 inhibitor, the post-
obstruction intraluminal pressure increase was significantly
lower than in controls, indicating that increased COX-2 ex-
pression plays a part in elevated pressure in the upper urinary
tract during obstruction.9
FIG. 4. Log-transformed values of the measured TNF-a
mRNA expression normalized for b-actin (95%CI). $p < 0.05
(0.05–0.005) distal part of the ureter compared with the
proximal part within each group. *p<0.05 (0.05–0.001) com-
pared with controls. Short term = 2 minutes.
FIG. 3. Ureteral expression of TNF-a mRNA (arbitrary
units). The depicted values are calculated group means ac-
cording to Table 2. *p < 0.05 (0.05–0.001) compared with
controls. $p < 0.05 (0.05–0.005) distal part of the ureter
compared with the proximal part within each group. Short
term = 2 minutes. TNF-a = tumor necrosis factor-a.
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A few studies exist regarding the role and function of
TNF-a in the human ureter. In a study of 30 patients, serum
TNF-a levels were significantly increased after 1 and
48 hours following ureteroscopic lithotripsy,29 and in an-
other study it was found significantly more abundant in the
ureter of children with vesicoureteral reflux than in healthy
controls.12
COX-2 and TNF-a expression in the ureteral
wall in response to the use of UAS
The present study demonstrated that the use of UAS re-
sulted in a significant upregulation of COX-2 and TNF-a
mRNA expression. This was evident following just a few
minutes of UAS placement. The elevated expression levels
were comparable to what has previously been reported after
several hours of ureteral obstruction.8,9,11 Furthermore, this
effect persisted after 2 hours of rest and reperfusion before
tissue sampling was performed. To our knowledge this is the
first study showing such a substantial impact on COX-2 and
TNF-a expression in the ureter by what may be characterized
as a minimal surgical intervention.
After leaving the UAS in the ureter for 2 hours, we found
an upregulation of both COX-2 and TNF-a as much as nine-
fold compared to controls. This increase is twice as high as
what has previously been found in studies of COX-2 using
chronically obstructed human ureters and experimental ure-
teral obstruction in pigs.8,11 Similar studies regarding TNF-a
induction in the human ureter after instrumentation have not
been published; however, our results are supported by the
findings of Schwentner and colleagues,12 who showed that
TNF-a levels were significantly higher in children with ve-
sicoureteral reflux than in age-matched autopsy controls, and
by Bantis and colleagues,29 who found doubling of serum
values 1 hour after ureteroscopic lithotripsy.
Asmight be expected, the upregulation of pro-inflammatory
mediators was stronger and more significant in the long-term
UAS treatment group than in the short-term group (Tables 1
and 2; Figs. 1–4). It was noteworthy, however, that the ex-
pression in the short-term group was quite extensive, indi-
cating that even short endourologic procedures may elicit a
profound local inflammatory response, which in the ureter
may lead to tissue edema and postoperative upper urinary
tract obstruction. Comparing distal versus proximal ureteral
tissue samples, we found that expression levels of pro-
inflammatory mediators in the distal ureters were two to three
times higher than in the proximal. This was observed in both
groups. As the whole ureter is exposed to similar nervous and
humoral stimuli, it can be reasoned that the direct physical
stress applied to the distal ureter during insertion of the UAS
is more pronounced compared to the proximal part. Thus, the
distal ureter seems to be more vulnerable to UAS insertion
than its proximal counterpart.
Clinical implications
In literature some studies exist on possible physiologic
roles of COX-2 and TNF-a in the bladder and kidneys, but
much less can be found on the effects of upregulation of these
in the ureter. In bladder obstruction in mice, COX-2 activa-
tion occurs primarily in the smooth muscle cells in response
to mechanical stretch, which suggests that stretch-activated
COX-2 expression may play a role in bladder smooth muscle
cell proliferation and pathologic bladder wall thickening after
obstruction.30
Although no similar knowledge exists on the extended
effects following ureteral wall stretch, it can be hypothe-
sized that inflammatory responses in the ureter may also to
some degree stimulate smooth muscle cell proliferation
and connective tissue fibrosis, which are supported by the
findings of Lallas and colleagues.7 Considering the fact
that stone forming patients are likely to have multiple
procedures performed, the risk of developing strictures or
gradual loss of ureteral motor function may be consider-
able over time.
The effects of NSAID on pain and inflammation have long
been utilized in the treatment of acute renal colic.13 A se-
lective COX-2 inhibitor and a nonselective COX inhibitor
reduced ureteral contractility in both porcine and human
ureteral segments in vitro.14 Treatment with the COX-2 in-
hibitor, Celecoxib, completely abolished the expression of
COX-2 and prostaglandin E2 (PGE2) in the smooth muscle
layer of ligated ureters, and the severity of hydroureter and
fibrosis of the muscle layer was significantly attenuated in a
rat experiment.31 Another study on human ureter showed that
the selective COX-2 inhibitor NS-398 reduced tonic and
phasic contraction.32 In a swine study, diclofenac and NS-
398, effectively and reversibly, inhibited ureteral contrac-
tions.33 These studies show that reducing ureteral muscle
tone and activity, as well as reducing tissue fibrosis, is pos-
sible by means of COX inhibition.
Our data suggest that inhibition of COX-2 and TNF-a in
the ureter, during and after endourologic procedures, may be
a rational treatment option, potentially preventing pain and
postoperative urinary tract obstruction, which might be re-
flected in a reduced need for postoperative stenting. This
needs to be further confirmed in clinical trials, however.
Limitations
The UAS size (13/15F) used in the experiment may be
considered too large for clinical usage in humans, and this
may have resulted in an exaggerated COX-2 and TNF-a re-
sponse. The ureters in the pigs chosen for the study were
slightly larger than human ureters, however, and the UAS
size 13/15F was chosen to reflect clinical usage of UAS 12/
14F in humans. Still, comparisons of pro-inflammatory me-
diator responses between smaller and larger sheaths would
have added valuable information to the data. In the present
series only the effect of UAS placement was evaluated.
Merely introducing an ureteroscope into the ureter possibly
also would have resulted in increased upregulation of pro-
inflammatory mediators. However, it is conceivable to be-
lieve that the response to a UAS, which necessarily has to be
larger than the ureteroscope itself, will be more pronounced.
Since our study did not include an ureteroscope arm, differ-
ences in the ureteral response between ureteroscope alone
and usage of UAS could not be clarified, and this issue needs
further investigations. In contrast, manipulation with an ur-
eteroscope inside a UAS during RIRS may result in further
friction between the UAS and the ureteral wall, potentially
resulting in an even more pronounced inflammatory re-
sponse. In addition, the role of prestenting, which in a clinical
setting often will be done when a larger sized UAS is to be
used, cannot be concluded upon from the present data.
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Conclusion
The pro-inflammatory mediators COX-2 and TNF-a were
significantly upregulated in the ureteral wall by the influence
of UASs. These findings may have implications for postop-
erative pain, drainage, and complications. Thus, selective
inhibition of COX-2 and TNF-amay be a way to reduce UAS
induced morbidity. This needs to be confirmed in future ex-
periments and clinical trials.
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